321 related articles for article (PubMed ID: 19468270)
1. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Dombret H; Preudhomme C; Boissel N
Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
[TBL] [Abstract][Full Text] [Related]
3. Core binding factor acute myeloid leukemia.
Paschka P
Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
[TBL] [Abstract][Full Text] [Related]
4. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
6. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Büchner T; Berdel WE; Haferlach C; Haferlach T; Schnittger S; Müller-Tidow C; Braess J; Spiekermann K; Kienast J; Staib P; Grüneisen A; Kern W; Reichle A; Maschmeyer G; Aul C; Lengfelder E; Sauerland MC; Heinecke A; Wörmann B; Hiddemann W
J Clin Oncol; 2009 Jan; 27(1):61-9. PubMed ID: 19047294
[TBL] [Abstract][Full Text] [Related]
7. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Solh M; Yohe S; Weisdorf D; Ustun C
Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818
[TBL] [Abstract][Full Text] [Related]
8. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
[TBL] [Abstract][Full Text] [Related]
9. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
Appelbaum FR; Kopecky KJ; Tallman MS; Slovak ML; Gundacker HM; Kim HT; Dewald GW; Kantarjian HM; Pierce SR; Estey EH
Br J Haematol; 2006 Oct; 135(2):165-73. PubMed ID: 16939487
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia.
Nakasone H; Izutsu K; Wakita S; Yamaguchi H; Muramatsu-Kida M; Usuki K
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1262-9. PubMed ID: 18940681
[TBL] [Abstract][Full Text] [Related]
11. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
[TBL] [Abstract][Full Text] [Related]
12. Core binding factor acute myeloid leukemia (CBF-AML) in México: a single institution experience.
Ruiz-Delgado GJ; Macías-Gallardo J; Lutz-Presno J; Garcés-Eisele J; Hernández-Arizpe A; Montes-Montiel M; Ruiz-Argüelles GJ
Rev Invest Clin; 2011; 63(1):25-30. PubMed ID: 21574542
[TBL] [Abstract][Full Text] [Related]
13. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
[TBL] [Abstract][Full Text] [Related]
14. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
[TBL] [Abstract][Full Text] [Related]
15. Core-binding factor acute myeloid leukemia.
Sangle NA; Perkins SL
Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
[TBL] [Abstract][Full Text] [Related]
16. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
Lück SC; Russ AC; Du J; Gaidzik V; Schlenk RF; Pollack JR; Döhner K; Döhner H; Bullinger L
Br J Haematol; 2010 Mar; 148(6):925-37. PubMed ID: 20064158
[TBL] [Abstract][Full Text] [Related]
17. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
18. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
[TBL] [Abstract][Full Text] [Related]
20. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
Paschka P; Döhner K
Hematology Am Soc Hematol Educ Program; 2013; 2013():209-19. PubMed ID: 24319183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
